Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides
- 1 December 2017
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (23) , 5179-5184
Abstract
No abstract availableKeywords
Funding Information
- NIH (U01MH087965)
This publication has 29 references indexed in Scilit:
- Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100Neuropsychopharmacology, 2014
- Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of SchizophreniaNeuropsychopharmacology, 2011
- Allosteric Antipsychotics: M4 Muscarinic Potentiators as Novel Treatments for SchizophreniaNeuropsychopharmacology, 2010
- Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic PropertiesNeuropsychopharmacology, 2009
- Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Allosteric modulation of the muscarinic M4receptor as an approach to treating schizophreniaProceedings of the National Academy of Sciences, 2008
- Cholinergic Agonists as Novel Treatments for Schizophrenia: The Promise of Rational Drug Development for PsychiatryAmerican Journal of Psychiatry, 2008
- Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for SchizophreniaAmerican Journal of Psychiatry, 2008
- An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmissionNature Chemical Biology, 2007
- Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer DiseaseArchives of Neurology, 1997